PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+2.67%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$770M
AUM Growth
+$770M
(-11%)
Cap. Flow
-$82.4M
Cap. Flow
% of AUM
-10.7%
Top 10 Holdings %
Top 10 Hldgs %
76.77%
Holding
47
New
8
Increased
7
Reduced
11
Closed
2
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$38.7M |
| 2 |
PTC Therapeutics
PTCT
|
$9.81M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$8.69M |
| 4 |
BioNTech
BNTX
|
$2.99M |
| 5 |
Edwards Lifesciences
EW
|
$2.6M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$30M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$18.9M |
| 3 |
Insmed
INSM
|
$14.5M |
| 4 |
Biogen
BIIB
|
$11.7M |
| 5 |
STAAR Surgical
STAA
|
$10.8M |
Sector Composition
| 1 | Healthcare | 98.76% |
| 2 | Financials | 1.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $142M | 18.4% | 1,940,993 -197,970 | -9% | -$14.5M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $87M | 11.3% | 8,145,311 -884,532 | -10% | -$9.45M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $76.6M | 9.95% | 1,090,056 -40,111 | -4% | -$2.82M |
|
|
4
United Therapeutics
UTHR
$13.8B
| $65.7M | 8.53% | 183,246 -83,668 | -31% | -$30M |
|
|
5
Biogen
BIIB
$19.4B
| $44.4M | 5.76% | 228,916 -60,134 | -21% | -$11.7M |
|
|
6
STAAR Surgical
STAA
$1.36B
| $40.6M | 5.27% | 1,091,608 -290,011 | -21% | -$10.8M |
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $38.8M | 5.04% | 2,523,956 +105,115 | +4% | +$1.62M |
|
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $38.7M | 5.03% | +140,681 | New | +$38.7M |
|
9
Prothena Corp
PRTA
$441M
| $29.1M | 3.78% | 1,737,964 +71,586 | +4% | +$1.2M |
|
|
10
Iovance Biotherapeutics
IOVA
$807M
| $28.6M | 3.71% | 3,041,685 +925,282 | +44% | +$8.69M |
|
11
AnaptysBio
ANAB
$569M
| $28.3M | 3.67% | 843,971 +40,330 | +5% | +$1.35M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $26.3M | 3.41% | 210,258 +8,575 | +4% | +$1.07M |
|
13
Alkermes
ALKS
$4.78B
| $10.8M | 1.4% | 384,656 -110,936 | -22% | -$3.11M |
|
|
14
PTC Therapeutics
PTCT
$3.92B
| $9.81M | 1.27% | +264,469 | New | +$9.81M |
|
15
Align Technology
ALGN
$10.3B
| $9.61M | 1.25% | 37,772 | – | – |
|
16
eHealth
EHTH
$118M
| $9.58M | 1.24% | 2,347,519 -2,671 | -0.1% | -$10.9K |
|
17
NovoCure
NVCR
$1.38B
| $9.28M | 1.21% | 593,540 +31,632 | +6% | +$494K |
|
|
SLRN
18
DELISTED
ACELYRIN
SLRN
| $8.84M | 1.15% | 1,792,895 +77,715 | +5% | +$383K |
|
|
RVNC
19
DELISTED
Revance Therapeutics, Inc.
RVNC
| $8.37M | 1.09% | 1,611,787 -3,645,299 | -69% | -$18.9M |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.8M | 1.01% | 405,193 | – | – |
|
|
SAGE
21
DELISTED
Sage Therapeutics
SAGE
| $7.3M | 0.95% | 1,010,833 | – | – |
|
22
Gossamer Bio
GOSS
$562M
| $6.19M | 0.8% | 6,277,093 | – | – |
|
23
Karyopharm Therapeutics
KPTI
$61.7M
| $4.23M | 0.55% | 5,102,193 | – | – |
|
|
NVRO
24
DELISTED
NEVRO CORP.
NVRO
| $4.19M | 0.54% | 750,371 | – | – |
|
|
25
BioNTech
BNTX
$24B
| $2.99M | 0.39% | +25,206 | New | +$2.99M |
|